Novocure GmbH
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Device: NovoTTF-200T
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 69
- Registration Number
- NCT06558799
- Locations
- 🇦🇹
Universitätsklinik f. Innere Medizin III, Salzburg, Austria
🇨🇿Vitkovicka Nemocnice, Ostrava, Czechia
🇨🇿General University Hospital in Prague, Clinic of Oncology, Prague, Czechia
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 741
- Registration Number
- NCT06556563
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷Centre Hospitalier Universitaire de Lyon, Bron, France
🇫🇷Hopital de la Timone, Marseille, France
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 734
- Registration Number
- NCT06216301
- Locations
- 🇺🇸
Luminis Health Radiation Oncology - Anne Arundel Health System, Annapolis, Missouri, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Abramson Cancer Center, Philadelphia, Pennsylvania, United States
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
- Conditions
- Pleural Mesothelioma
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 198
- Registration Number
- NCT05538806
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Lungenklinik Gauting, Gauting, Bavaria, Germany
🇩🇪University Hospital Regensburg, Regensburg, Bavaria, Germany
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
- Conditions
- COVID-19
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04953234
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
- Prev
- 1
- 2
- Next